Concord Biotech Ltd (CONCORDBIO) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by Concord Biotech Ltd on NSE and BSE, with an AI summary of each filing.
Transcript of Q2 - FY27 Earnings call held on October 28, 2026
Transcript · 03 Nov 2026, 9:01 pm
Earning Call Recording- For the Second Quarter and half year ended on September 30, 2026
Audio / Video · 29 Oct 2026, 12:11 am
Concord Biotech Releases Q2FY27 Earnings Call Audio Recording Concord Biotech hosted its Q2 and H1 ended 30th Sep'26 earnings conference call on 28th Oct'26 at 3:30 PM IST to discuss its unaudited standalone and consolidated financial results. Pursuant to Regulation 30 of SEBI LODR Regulations, the company announced that the complete audio recording of the earnings call has been made publicly accessible on its official website.
Intimation of Schedule of Analyst / Institutional Investor meetings under the SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015 to be held on 03rd and 4th November, 2026.
Intimation · 28 Oct 2026, 8:37 pm
Concord Biotech to Attend UBS Non-Deal Roadshow in Singapore Concord Biotech Limited announced that company officials will participate in-person at a Non-Deal Roadshow organized by UBS in Singapore on 3rd and 4th Nov'26. Discussions with analysts and institutional investors will focus exclusively on publicly available information, with no unpublished price-sensitive information being shared.
Investor''s presentation on unaudited standalone and consolidated financial results for the second quarter and half year ended on September 30, 2026
Investor Presentation · 28 Oct 2026, 1:51 am
Concord Biotech Reports Solid Q2FY27 Results, Approves 1:1 Bonus Issue Concord Biotech delivered strong consolidated performance for the period ended 30th Sep'26, with Q2FY27 revenue rising 25.1% YoY to ₹309.1 Cr, driven by broad-based demand and a 30% expansion in API sales to ₹250.2 Cr. EBITDA grew 18.0% YoY to ₹104.4 Cr (33.8% margin), while PAT climbed 10.3% YoY to ₹69.6 Cr. For H1FY27, revenue reached ₹566.6 Cr (+25.6% YoY) and PAT rose to ₹127.3 Cr (+19.0% YoY). The company approved a 1:1 bonus share issue, launched dermatology division Inspira, and secured ANDA approvals for Tofacitinib and MMF OS.
The Board of Directors at its meeting held on October 27, 2026 has fixed Wednesday, November 04, 2026 as record date for issuance of Bonus equity shares in the ratio of 1:1.
Bonus Issue · 28 Oct 2026, 12:57 am
Concord Biotech Sets Record Date for 1:1 Bonus Share Issue Concord Biotech Limited’s Board of Directors has fixed 4th Nov'26 as the record date to determine shareholder eligibility for its 1:1 bonus equity share issue (one bonus share for every one existing fully paid-up share held). Subject to regulatory and statutory approvals, the deemed date of allotment for the bonus shares is set for 5th Nov'26.
Unaudited Standalone and Consolidated Financial Results for the second quarter and half year ended on September 30, 2026.
Financial Result · 28 Oct 2026, 12:52 am
Concord Biotech Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.
Outcome · 28 Oct 2026, 12:38 am
The Board of Directors of the Company, at its meeting held today i.e. Tuesday, October 27, 2026, has inter-alia considered and approved the Un-audited financial results for the quarter ....
Outcome · 28 Oct 2026, 12:33 am
Concord Biotech Ltd - Financial Result for the Quarter ended 30th Sep'26 (Consolidated, INR Lakh) ■ Revenue: 30,907 (+25.1% YoY | +20.0% QoQ) ■ EBITDA: 10,438 (+18.0% YoY | +26.7% QoQ) ■ EBITDA Margin (%): 33.8 (-205 bps YoY | +178 bps QoQ) ■ PAT: 7,065 (+11.1% YoY | +20.7% QoQ) ■ EPS (INR): 6.65 (+10.3% YoY | +20.5% QoQ)
Earnings Call Invite for the operational and financial performance of the Company for the Quarter and half year ended on September 30, 2026
Intimation · 28 Oct 2026, 3:30 pm
Concord Biotech Schedules Q2FY27 Earnings Conference Call for 28th Oct'26 Concord Biotech Limited will host an earnings conference call on 28th Oct'26 at 3:30 PM IST to discuss its unaudited standalone and consolidated financial and operational performance for Q2FY27 and the half-year ended 30th Sep'26. The call will be hosted by Choice Institutional Equities and attended by key management, including Chairman & MD Sudhir Vaid, Joint MD & CEO Ankur Vaid, and CFO Raviraj Karia. Primary access numbers include +91 22 6280 1395 and +91 22 7115 8112.
To consider and approve the financial results for the period ended September 30, 2026
Intimation · 27 Oct 2026, 5:30 am
CONCORD BIOTECH LIMITED has informed the Exchange about Board Meeting to be held on 27-Oct-2026 to inter-alia consider and approve the Unaudited Financial results of the Company for the Half Yearly ended September 2026 .
Intimation · 27 Oct 2026, 5:30 am
Concord Biotech Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/10/2026 ,inter alia, to consider and approve unaudited Standalone and Consolidated ....
Intimation · 27 Oct 2026, 5:30 am
Concord Biotech Board to Consider Q2 and H1 Results on 27th Oct'26 Concord Biotech Ltd announced that its Board of Directors will meet on 27th Oct'26 to consider and approve the unaudited standalone and consolidated financial results for the quarter and half-year ended 30th Sep'26, alongside the Limited Review Report from Statutory Auditors. In compliance with insider trading regulations, the trading window for dealing in company securities remains closed for designated persons and their immediate relatives until 48 hours post the declaration of the financial results.
The Board of Director at its meeting held today i.e. Wednesday, September 23, 2026, has inter-alia considered and approved Issuance of Bonus shares & Increase in the Authorised Share Capital ....
Outcome · 23 Sept 2026, 10:37 pm
Concord Biotech Approves 1:1 Bonus Issue and Authorised Capital Increase Concord Biotech's board approved a 1:1 bonus issue on 23rd Sep'26, issuing 10,46,16,204 equity shares of Rs 1 each by capitalizing Rs 10.46 cr from its share premium account (available balance of Rs 81.97 cr as of 31st Mar'26). Consequently, paid-up capital will double from Rs 10.46 cr to Rs 20.92 cr, with dispatch estimated by 22nd Nov'26. The board also approved doubling the authorised share capital to Rs 22 cr (22 cr shares of Rs 1 each), subject to shareholder approval.
To consider bonus
Intimation · 19 Sept 2026, 7:35 pm
CONCORD BIOTECH LIMITED has informed the Exchange about Board Meeting to be held on 23-Sep-2026 to consider and approve Increase in authorised capital/Bonus.
Intimation · 19 Sept 2026, 7:26 pm
Concord Biotech Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 23/09/2026 ,inter alia, to consider and approve the proposal for declaration ....
Intimation · 19 Sept 2026, 7:24 pm
Concord Biotech Board to Consider Bonus Share Issue on 23rd Sep'26 Concord Biotech Limited has scheduled a Board of Directors meeting on 23rd Sep'26 to consider a proposal for the issuance of bonus equity shares to existing shareholders, subject to shareholder approval. In compliance with insider trading regulations, the trading window for designated persons and their immediate relatives has been closed effective 19th Sep'26 and will reopen on 26th Sep'26, 48 hours post the declaration of the board meeting outcome.
Intimation of Outcome of U.S. Food and Drug Administration (USFDA) Inspection at Unit II - Valthera Formulation Facility of the Company.
Others (Uncategorized) · 18 Sept 2026, 3:52 pm
USFDA Concludes Inspection at Concord Biotech’s Valthera Facility With One Minor Observation The USFDA concluded an inspection at Concord Biotech's Unit II formulation facility in Valthera, Gujarat, on 18th Sep'26. The regulator issued one minor procedural observation that is not related to Good Manufacturing Practices (GMP). The company plans to submit a comprehensive response within the stipulated timeline and stated that the outcome will have no material impact on current business operations or existing product supplies from the facility.
Pursuant to Regulation 30(6) read with Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements), Regulations, 2015, as amended from time ....
Intimation · 17 Sept 2026, 4:38 pm
Concord Biotech Schedules Group Investor Meeting via JP Morgan Healthcare Trip Concord Biotech Limited has scheduled an analyst and institutional investor interaction on 23rd Sep'26 at 12:30 PM in Ahmedabad. The group meeting is organized by JP Morgan Healthcare Trip. Discussions will strictly involve publicly available information with no unpublished price sensitive information (UPSI) shared, subject to exigency-based changes.
We would like to inform you that the officials of the Company will be attending an Investor Conference on 26th August 2026 as per the schedule and details in the file uploaded herewith.
Intimation · 21 Aug 2026, 3:44 pm
Concord Biotech Schedules Investor Meeting with Phillip Capital Concord Biotech Limited officials will attend an investor conference organized by Phillip Capital PCG on 26-Aug'26, from 01:00 PM to 03:00 PM IST. The group meeting will take place in Ahmedabad. The company has stated that discussions will be based solely on publicly available information, with no unpublished price-sensitive information (UPSI) to be shared. The schedule is subject to change.
Transcript of Q1 - FY27 Earnings call held on August 03, 2026
Transcript · 07 Aug 2026, 8:31 pm
The audio recording of the conference held on August 03, 2026 has been hosted on the website of the company and link to access the said recording is as follows: - Link : https://concordbiotech.com/wp-content/uploads/2026/08/Concord-Biotech-Q1-FY27-Earnings-Call-Audio-Recording.mp3 ....
Audio / Video · 03 Aug 2026, 11:38 pm
Concord Biotech Q1 FY27 Earnings Call Recording Made Available Concord Biotech has released the audio recording of its earnings call held on 03 Aug'26. The call discussed the unaudited standalone and consolidated financial results for the first quarter ending 30 Jun'26. The recording is now accessible on the company's website, providing investors and analysts with direct insights into management's commentary on the quarterly performance and outlook. This follows the company's initial earnings call announcement on 28 Jul'26.
Investors'' Presentation on unaudited Standalone and Consolidated Financial Results for the first quarter ended June 30, 2026
Investor Presentation · 02 Aug 2026, 12:22 am
Concord Biotech Q1FY27: Strong Revenue Growth and Margin Expansion Concord Biotech reported strong Q1FY27 results, with revenue growing 26% YoY to ₹257.5 Cr, driven by robust API segment performance (+42% YoY) and a 46% YoY increase in exports. EBITDA rose 34% YoY to ₹82.4 Cr, with the margin expanding 190 bps to 32.0%. PAT grew 31% YoY to ₹57.7 Cr, and PAT margin improved by 80 bps to 22.4%. The company received USFDA approvals for two ANDAs and strengthened global regulatory credentials with inspections from Brazil, Kenya, and Uganda.
Pursuant to regulation 44(3) of the SEBI (LODR) Regulations, 2015 and section 108 of the Companies Act, 2013, the voting results along with the scrutinizers report for the business items ....
Annual General Meeting · 01 Aug 2026, 11:15 pm
The 41st Annual General Meeting Meeting of the Members of the Company was held on Friday July, 31, 2026 at 12:00 Noon through VC/OAVM. The summary of the proceedings are published herewith.
Annual General Meeting · 01 Aug 2026, 1:18 am
Unaudited Standalone and Consolidated Financial Results for the first quarter ended on June 30, 2026
Financial Result · 01 Aug 2026, 12:00 am
Concord Biotech Q1 FY27: Revenue and Profit Beat on Strong YoY Growth Concord Biotech reported strong Q1 FY27 consolidated results with revenue from operations at ₹25,748.90 lakhs, a 26.2% YoY increase but a 21.0% QoQ decline. Profit after tax (PAT) grew 31.0% YoY to ₹5,769.69 lakhs, though it fell 34.8% QoQ from a high base in Q4 FY26. Consolidated EPS for the quarter ending 30-Jun'26 stood at ₹5.52, up from ₹4.21 YoY. Total expenses increased 20.5% YoY to ₹19,324.91 lakhs, mainly driven by higher material and employee benefit costs.